[go: up one dir, main page]

WO2005055920A3 - Compositions et methodes de traitement de troubles psychiatriques - Google Patents

Compositions et methodes de traitement de troubles psychiatriques Download PDF

Info

Publication number
WO2005055920A3
WO2005055920A3 PCT/IL2004/001117 IL2004001117W WO2005055920A3 WO 2005055920 A3 WO2005055920 A3 WO 2005055920A3 IL 2004001117 W IL2004001117 W IL 2004001117W WO 2005055920 A3 WO2005055920 A3 WO 2005055920A3
Authority
WO
WIPO (PCT)
Prior art keywords
dopamine
treatment
cells
psychiatric disorders
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2004/001117
Other languages
English (en)
Other versions
WO2005055920A2 (fr
Inventor
Michal Eisenbach-Schwartz
Jonathan Kipnis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of WO2005055920A2 publication Critical patent/WO2005055920A2/fr
Anticipated expiration legal-status Critical
Publication of WO2005055920A3 publication Critical patent/WO2005055920A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un agent sélectionné parmi (i) la dopamine, (ii) un précurseur de la dopamine, (iii) un agoniste D1-R de la dopamine, (iv) un mélange de dopamine et d'un précurseur de dopamine, (v) un mélange de dopamine, d'un précurseur de dopamine ou d'un agoniste D1-R de dopamine avec un antagoniste D2-R de dopamine, (vi) un peptide du système nerveux central (SNC) modifié, (vii) des lymphocytes qui ont été activés par un antigène spécifique de SNC ou par un peptide SNC modifié, et (viii) poly-YE, un peptide ou un polypeptide lié à poly-YE. Ledit agent peut provoquer une régulation vers le bas de l'activité suppressive de lymphocytes régulateurs CD4+CD25+ sur des lymphocytes effecteurs CD4+CD25- (Teff), la modulation de la réponse immunitaire et/ou la modulation de la réponse auto-immune, et il est utilisé dans le traitement de troubles psychiatriques.
PCT/IL2004/001117 2003-12-09 2004-12-09 Compositions et methodes de traitement de troubles psychiatriques Ceased WO2005055920A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52777203P 2003-12-09 2003-12-09
US60/527,772 2003-12-09

Publications (2)

Publication Number Publication Date
WO2005055920A2 WO2005055920A2 (fr) 2005-06-23
WO2005055920A3 true WO2005055920A3 (fr) 2007-03-08

Family

ID=34676776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/001117 Ceased WO2005055920A2 (fr) 2003-12-09 2004-12-09 Compositions et methodes de traitement de troubles psychiatriques

Country Status (1)

Country Link
WO (1) WO2005055920A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US20100272787A1 (en) * 2007-12-21 2010-10-28 Ben Gurion University Of The Negev Amethod of treating neurodegenerative diseases
US20110033488A1 (en) * 2008-04-15 2011-02-10 Yeda Research And Development Co. Ltd. Agents and methods for treatment of anxiety disorders
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284638A (en) * 1978-11-21 1981-08-18 Ciba-Geigy Corporation Pharmaceutical compositions with central depressant and antipsychotic activity having a butyrophenone derivative which is substituted in the 4-position and a C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydro-pyridine
US5597832A (en) * 1993-04-06 1997-01-28 Abbott Laboratories Tetracyclic compounds as dopamine agonists
US20030003082A1 (en) * 2001-06-28 2003-01-02 Michal Eisenbach-Schwartz Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284638A (en) * 1978-11-21 1981-08-18 Ciba-Geigy Corporation Pharmaceutical compositions with central depressant and antipsychotic activity having a butyrophenone derivative which is substituted in the 4-position and a C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydro-pyridine
US5597832A (en) * 1993-04-06 1997-01-28 Abbott Laboratories Tetracyclic compounds as dopamine agonists
US20030003082A1 (en) * 2001-06-28 2003-01-02 Michal Eisenbach-Schwartz Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOTO K. ET AL.: "Depression in multiple system atrophy: a case report", PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol. 54, 2000, pages 507 - 511, XP008076875 *
HAUBEN E. ET AL.: "Autoimmune T cells as potential neuroprotective therapy for spinal cord injury", LANCET, vol. 355, 22 January 2000 (2000-01-22), pages 286 - 287, XP004814821 *
HAUBEN E. ET AL.: "Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease", JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 4, August 2001 (2001-08-01), pages 591 - 599, XP003008914 *
KIPNIS J. ET AL.: "Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppres the ability to withstand injury to the central nervous systm", PNAS, vol. 99, no. 24, 2002, pages 15620 - 15625, XP003008915 *
RACETTE B.A.: "levodopa responsive parkinsonism in an adult with Huntington's disease", J. NEUROL. NEUROSURG. PSYCHIATRY, vol. 65, 1998, pages 577 - 579, XP003008913 *
SACKS O.W. ET AL.: "Effects of L-Dopa in patients with dementia", THE LANCET, vol. 295, no. 7658, 1970, pages 1231, XP003008916 *

Also Published As

Publication number Publication date
WO2005055920A2 (fr) 2005-06-23

Similar Documents

Publication Publication Date Title
EP2345671B8 (fr) Variantes FC optimisées et leurs procédés de génération
EP1470146B8 (fr) Anticorps contre l'antigene muc18
WO2006070286A3 (fr) Anticorps monoclonaux contre le nkg2a
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
IL180588A0 (en) Humanized anti-cmet antagonists
WO2003057837A8 (fr) Procedes d'utilisation d'anticorps anti-muc18
WO2006007529A3 (fr) Exosomes immunosuppresseurs
IL221366A0 (en) SOLUBLE zB7RI POLYPEPTIDE AND METHOD USING IT
SI1814878T1 (sl) Spojine spiro-2,4-pirimidindiamina in njihova uporaba
TW200510459A (en) RG1 antibodies and uses thereof
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2003072713A3 (fr) Utilisation de bcma comme agent immunoregulateur
WO2006073748A3 (fr) Methode de traitement de maladies auto-immunes par induction de la presentation d'antigene par des cellules presentatrices d'antigene induisant une tolerance
EP1818062A3 (fr) Anticorps anti HSP90
DE60134645D1 (de) Amidinderivate als selektive nmda-rezeptorantagonisten
WO2005055920A3 (fr) Compositions et methodes de traitement de troubles psychiatriques
WO2004075863A3 (fr) Antagonistes de cxcr3
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
HK1046925A1 (zh) Mage-a12抗原肽及其用途
EP1601687A4 (fr) Procedes pour augmenter la proliferation des lymphocytes b
WO2004019965A3 (fr) Approches tolerogenes a base de thymus destinees au diabete de type i.
WO2003091383A3 (fr) Epitopes t de l'antigene epha2.
WO2000040722A3 (fr) Genes de synthese de l'insuline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase